DK2174956T3 - Sammensætninger til anti-fibrinolytisk behandling - Google Patents

Sammensætninger til anti-fibrinolytisk behandling

Info

Publication number
DK2174956T3
DK2174956T3 DK08787634.8T DK08787634T DK2174956T3 DK 2174956 T3 DK2174956 T3 DK 2174956T3 DK 08787634 T DK08787634 T DK 08787634T DK 2174956 T3 DK2174956 T3 DK 2174956T3
Authority
DK
Denmark
Prior art keywords
compositions
fibrinolytic treatment
fibrinolytic
treatment
Prior art date
Application number
DK08787634.8T
Other languages
English (en)
Inventor
Lopategui Josune Orbe
Fernandez Jose Antonio Paramo
Garcia Jose Antonio Rodriguez
Vargas Rosario Serrano
Original Assignee
Proyecto Biomedicina Cima Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proyecto Biomedicina Cima Sl filed Critical Proyecto Biomedicina Cima Sl
Application granted granted Critical
Publication of DK2174956T3 publication Critical patent/DK2174956T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/8146—Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
DK08787634.8T 2007-06-26 2008-06-26 Sammensætninger til anti-fibrinolytisk behandling DK2174956T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200701786A ES2313841B1 (es) 2007-06-26 2007-06-26 Composiciones para tratamiento anti-fibrinolitico.
PCT/ES2008/000453 WO2009000957A1 (es) 2007-06-26 2008-06-26 Composiciones para tratamiento anti-fibrinolitico

Publications (1)

Publication Number Publication Date
DK2174956T3 true DK2174956T3 (da) 2012-10-01

Family

ID=40185221

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08787634.8T DK2174956T3 (da) 2007-06-26 2008-06-26 Sammensætninger til anti-fibrinolytisk behandling

Country Status (11)

Country Link
US (1) US8257701B2 (da)
EP (1) EP2174956B1 (da)
JP (1) JP2010531341A (da)
CN (1) CN101918441B (da)
AU (1) AU2008269686B8 (da)
BR (1) BRPI0813222A2 (da)
CA (1) CA2692986A1 (da)
DK (1) DK2174956T3 (da)
ES (2) ES2313841B1 (da)
RU (1) RU2453337C2 (da)
WO (1) WO2009000957A1 (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2271668T3 (da) 2008-03-24 2018-03-05 Salman Rahman Adam-15-antistoffer og immunogene peptider
EP2621956A2 (en) 2010-10-01 2013-08-07 Salman Rahman Methods for the development of metzincin-selective catalytic cleft directed antibodies for therapeutic and diagnostic applications
WO2015107139A1 (en) * 2014-01-17 2015-07-23 Proyecto De Biomedicina Cima, S.L. Compounds for use as antifibrinolytic agents
RU2657756C2 (ru) * 2016-08-30 2018-06-15 Общество с ограниченной ответственностью "ПРОФИТ ФАРМ" Способ лечения кровотечений из верхних отделов желудочно-кишечного тракта
US11654057B2 (en) 2020-04-09 2023-05-23 Bio 54, Llc Devices for bleeding reduction and methods of making and using the same
US11642324B1 (en) 2022-03-01 2023-05-09 Bio 54, Llc Topical tranexamic acid compositions and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830468A (en) * 1995-05-17 1998-11-03 The New York Blood Center, Inc. Fibrin(ogen) degradation by fibrinolytic matrix metalloproteinase
WO1999025687A1 (en) * 1997-11-14 1999-05-27 G.D. Searle & Co. Aromatic sulfone hydroxamic acid metalloprotease inhibitor
JPH11318449A (ja) * 1998-03-10 1999-11-24 Fuji Chem Ind Ltd ストロメライシン―２（ｍｍｐ―１０）に対する抗体
EP1060747A3 (en) * 1999-06-16 2001-12-05 New York Blood Center, Inc. Fibrin(ogen) degradation and clot lysis by fibrinolytic metalloproteinase
IL132558A0 (en) * 1999-10-25 2001-03-19 Compugen Ltd Variants of alterntive splicing
SE0100903D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds

Also Published As

Publication number Publication date
EP2174956A1 (en) 2010-04-14
JP2010531341A (ja) 2010-09-24
CN101918441B (zh) 2013-06-19
RU2453337C2 (ru) 2012-06-20
US8257701B2 (en) 2012-09-04
CA2692986A1 (en) 2008-12-31
AU2008269686B8 (en) 2013-02-14
RU2010102090A (ru) 2011-08-10
BRPI0813222A2 (pt) 2014-12-23
EP2174956B1 (en) 2012-06-27
WO2009000957A1 (es) 2008-12-31
EP2174956A4 (en) 2011-05-25
CN101918441A (zh) 2010-12-15
ES2313841A1 (es) 2009-03-01
ES2390391T3 (es) 2012-11-12
ES2313841B1 (es) 2010-01-12
US20100135986A1 (en) 2010-06-03
AU2008269686A1 (en) 2008-12-31
AU2008269686B2 (en) 2013-01-10

Similar Documents

Publication Publication Date Title
PL3354276T3 (pl) Kompozycje do leczenia zapalenia przewodu pokarmowego
DK2061561T3 (da) Sammensætninger til behandling af cancer
BRPI0810634A2 (pt) Composições fungicidas
HUE059171T2 (hu) Kompozíciók
DK2634231T3 (da) Sammensætninger
BRPI0906749A2 (pt) Composição
BRPI0913808A2 (pt) composição
BRPI0813775A2 (pt) Composição
RU2493831C3 (ru) Фармацевтические композиции
ES2628203T8 (es) Composiciones antitranspirantes
ATE528048T1 (de) Schweisshemmende/desodorierende zusammensetzung
BRPI0914427A2 (pt) composição dental endurecivel
BRPI0917231A2 (pt) composição
DK3300729T3 (da) Terapeutiske sammensætninger indeholdende macitentan
EP2144635A4 (en) STERILIZING COMPOSITION
EP2335669A4 (en) COMPOSITION FOR MEANS FOR DESENSIBILIZING TEETH
BRPI0810557A2 (pt) composição
BRPI0811274A2 (pt) Composição
BRPI0812592A2 (pt) Composição assada
EP2236149A4 (en) MEDICAL COMPOSITION
PT2182988E (pt) Composição radiofarmacêutica
BRPI0807920A2 (pt) Composições epilatórias
BRPI0820198A2 (pt) composições farmacêuticas
BRPI0811002A2 (pt) Composição biofertilizante
BRPI0820960A2 (pt) composição